Fellowship Overview
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020 and AMVUTTRA ® (vutrisiran) in 2022. Alnylam is advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Alnylam, based in Cambridge, MA, is offering a one year paid safety and risk management physician fellowship for medical toxicologists including fellows graduating in 2027, recent grads and those who may already be mid-career. This fellowship provides an opportunity for medical toxicologists to gain the skills, knowledge, and experience needed to pursue a career in the competitive biopharmaceutical industry, enabling them to become successful leaders and innovators in various areas of drug development.
The SRM team oversees all activities related to the detection, assessment, understanding, and prevention of adverse effects or other medicine-related safety concerns to ensure safe use of medicines and to safeguard health of patients. The fellow can expect to gain a thorough understanding and hands-on experience of pharmacovigilance (PV) activities and actively participate in the development and maintenance of the drug safety profiles for our revolutionary RNAi platform.
Summary of Key Responsibilities
- Provide scientific and operational assistance to safety product leads to support the ongoing development of Alnylam products
- Participate in collection, interpretation and presentation of safety data in internal forums, including but not limited to Safety Risk Management Team meetings
- Participate in signal detection and management activities under the lead of safety physicians and PV scientists
- Engage in ongoing safety data review, analysis, and reporting of safety data to internal and external stakeholders including HCPs and Regulatory Agencies
- Provide scientific and operational support to planning, management and authoring of safety aggregate reports (PBRERs, DSURs)
- Participate in development and management of Risk Management Plans
- Assist in the process of global literature review
Qualifications
Alnylam prides itself on its entrepreneurial, fast-paced environment where success is rapidly rewarded. There is a strong pipeline, significant resources, and every intention of continuing the phenomenal rate of success and growth. The culture values hard-work, creativity, flexibility, a sense of humor and a hands-on, problem-solving attitude.
- Medical Degree (MD) with a completed Residency program.
- Completed Medical Toxicology fellowship.
- Sound clinical acumen and a wide range of therapeutic area knowledge.
- Ability to synthesize and analyze safety data from various sources.
- Proficiency in problem-solving within a highly complex environment.
- Strong communications skills, both written and spoken, ideally with demonstrable experience in medical / scientific writing.
- Excellent interpersonal and decision-making skills. Strong influencing skills with the ability to quickly earn credibility across other functional areas.
- Ability to work in a fast-paced environment with rapidly approaching timelines.
- Knowledge of clinical research methodology, clinical epidemiology and biostatistics tools preferred.
- Experience in clinical development is a benefit but not required.
Terms of Fellowship
- Full time; Generous and competitive salary package, including health insurance; yhis fellowship is fully in office at Alnylam headquarters in Cambridge, MA.
Applications are due September 30th, 2026.